The largest share of the global eye allergy treatment market, comprising 69.00% in 2017, belonged to the seasonal and perennial allergic conjunctivitis segment. This segment, valued at USD 1,185.42 million in 2017, is predicted to grow at a CAGR of 5.33% during the forecast period. The prevalence of seasonal and perennial allergic conjunctivitis is a major factor contributing to its significant market share. Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are the most common types of allergic conjunctivitis, affecting about 98% of people experiencing eye allergies. According to the Virtual Medical Centre and The College of Optometrists, SAC is one of the most widespread eye problems, impacting approximately one-fifth of adults.
The vernal keratoconjunctivitis segment, valued at USD 215.13 million in 2017, is anticipated to be the second-largest lucrative segment, showing a projected CAGR of 5.31%. The growth in this segment is attributed to the increasing cases of vernal keratoconjunctivitis, especially among males. According to the National Center for Biotechnology Information (NCBI), this condition is most prevalent among boys in warm, dry, subtropical regions such as the Mediterranean, the Middle East, Central and West Africa, Latin America, and Asian countries like Japan, Thailand, and India. NCBI also notes a male-to-female ratio of 3.2:1 in patients under 20 years of age for vernal keratoconjunctivitis.
In contrast, the atopic keratoconjunctivitis segment is expected to register the highest CAGR of 5.34%. This suggests a significant growth trend in the treatment of atopic keratoconjunctivitis compared to other segments.
The global eye allergy treatment market is categorized based on types, including seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis.
The giant papillary conjunctivitis segment is projected to have the smallest market share during the forecast period. This is attributed to its limited impact, primarily affecting individuals who wear contact lenses. As a result, the prevalence of giant papillary conjunctivitis is expected to be lower compared to other segments.
In summary, the global eye allergy treatment market is dominated by the seasonal and perennial allergic conjunctivitis segment, driven by its high prevalence. The vernal keratoconjunctivitis segment follows as the second-largest, with increasing cases among the male population. The atopic keratoconjunctivitis segment is expected to exhibit the highest growth, while giant papillary conjunctivitis is anticipated to have the least impact due to its association with contact lens wearers.
Report Attribute/Metric | Details |
---|
Global Eye Allergy Treatment Market Revenue, by Treatment, 2017 (USD Mn)
Sources: MRFR Analysis
Eye Allergy Treatment Market Segmentation
Global eye allergy treatment market has been segmented into type, treatment, and end user.
On the basis of type, it is segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, giant papillary conjunctivitis, and others. Vernal keratoconjunctivitis includes palpebral, limbal, corneal, and others.
On the basis of treatment, the eye allergy treatment market has been segmented into medication, allergy shots (immunotherapy), and others. Medication includes artificial tears, decongestants, oral antihistamines, antihistamine/mast-cell stabilizers, corticosteroids. Decongestants are further sub-segmented into with or without antihistamines. Allergy shots (immunotherapy) is sub-segmented into Subcutaneous Immunotherapy Treatment (SCIT) and Sublingual Immunotherapy Treatment (SLIT). The medication segment is projected to value 1860.78 million in 2023. Its larger market share is due to its effectiveness for the treatment of eye allergy. Moreover, with a lot of options available in the eye allergy treatment market, patients find medications much more acceptable in most cases. The wide acceptance of artificial tear as a first-line treatment option for eye allergy is driving the market.
On the basis of end user, it is segmented into eye hospitals & clinics, medical institutes, research centers, and others.
Global Eye Allergy Treatment Market Share, by Region, 2017 (%)
Â
Sources: MRFR Analysis
Eye Allergy Treatment Market Regional Analysis
The Americas acquired the largest share of 40.4% is projected to grow at the highest CAGR during the forecast period. The growth of the Americas is due to its rising geriatric population and increasing ophthalmological disorders, causing an increased need for diagnosis and therapeutics. According to the National Eye Institute (NEI), about 3 million cases of conjunctivitis were reported in the US in 2015. This huge prevalence of eye allergies is driving the growth of the eye allergy treatment market.
Additionally, according to the US Census Bureau, in 2016, around 49.2 million residents were aged 65 and above in the US. This huge older population of the US contributed to over 15.2% of the total population which is likely to drive the market. Furthermore, the Americas is witnessing rampant advancements in technology. Thus, this increasing patient pool and increasing per capita income of citizens are going to propel the market growth of eye allergy treatments.
Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share owing to the rising patient population with eye disorders, availability of advanced treatment facilities, increasing healthcare expenditure, and the introduction of advanced therapies into the market along with the presence of good healthcare infrastructure. Additionally, rising government initiatives are driving the growth of the market. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired.
Asia-Pacific is the fastest-growing market for the global eye allergy treatment market. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the eye allergy treatment market in Asia-Pacific. Additionally, the rising elderly population is also fueling the market of eye allergy treatments in this region. According to the Asian Development Bank, Asia's elderly population is projected to reach nearly 923 million by 2050. This huge geriatric population is driving the growth of the market.
Eye Allergy Treatment Market Key Players
The prominent players in the global eye allergy treatment market are Allergan Plc, Johnson & Johnson Services Inc, Novartis AG, Bausch Health (Valeant Pharmaceuticals International Inc.), Santen Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Nicox, Akorn Inc., Shire, Nutra Essential OTC, and others.
Some of the key strategies followed by the players operating in the global eye allergy treatment market were innovation, product development, acquisition, and expansion.
Eye Allergy Treatment Market Segmentation
Global Eye Allergy Treatment Market, by Type
Global Eye Allergy Treatment Market, by Treatment
Global Eye Allergy Treatment Market, by End User
Global Eye Allergy Treatment Market, by Region
Available Additional Customizations
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)